Gateway Blog

Gateway Blog

High-Dose Vitamin C Therapy Kills Cancer Cells

By Admin at 12 Apr 2017

Researchers have now gained greater insights into how vitamin C may be harnessed to kill cancer cells, courtesy of a new study co-funded by Gateway for Cancer Research.

0 comments posted

Gateway-Funded Trial Shines Spotlight on Young Adult Cancer

By Admin at 4 Apr 2017

Each year, around 70,000 young adults are diagnosed with cancer in the United States, which accounts for five percent of cancer diagnoses in the country. This statistic is six times higher than the number of cancers diagnosed in children, age 14 and below.

0 comments posted

Can Cancer Interception Stop Cancer From Forming?

By Admin at 30 Mar 2017

Part of the challenge of winning the war against cancer lies in treating the disease in its later stages — a point at which many cancers become hard, if not impossible, to eliminate. Cancer interception may change that by targeting cancer at its earliest stages, in some cases even before it starts.

0 comments posted

Meet Kenneth: Kidney Cancer Survivor

By Admin at 29 Mar 2017

In honor of Kidney Cancer Awareness Month, we are spotlighting the courageous journey of Kenneth Monarrez, Gateway Associates Board member, who sought out a clinical trail to ultimately beat his cancer.

0 comments posted

Gateway Funded Trial Offers ADAPT Therapy for Advanced Colorectal Cancer

By Admin at 14 Mar 2017

The usual treatment for metastatic colorectal cancer includes chemotherapy, radiation and surgical resection. Unfortunately, the average survival rate has been only 20-24 months. In a Gateway-funded clinical trial led by Dr. Edward Lin, a survival rate of approximately 94+ months was achieved using a new approach called ADAPT – Activate tumor from Dormancy And Potentiate its Targeting.

0 comments posted



    2017 2016 2015
    99 cents of every dollar received directly funds cancer clinical trials


    Current Gateway-funded clinical trials


    Clinical trials funded at leading institutions worldwide


    Funds one patient for one day at a Gateway-funded clinical trial


    Mission Partners